Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8 + T cell effector differentiation and anti-tumor immunity

Lina Sun,Anjun Jiao,Haiyan Liu,Renyi Ding,Ning Yuan,Biao Yang,Cangang Zhang,Xiaoxuan Jia,Gang Wang,Yanhong Su,Dan Zhang,Lin Shi,Chenming Sun,Aijun Zhang,Lianjun Zhang,Baojun Zhang

DOI: https://doi.org/10.1038/s41392-024-01873-6

IF: 39.3

2024-06-27

Signal Transduction and Targeted Therapy

Abstract:CD8 + T cell immune responses are regulated by multi-layer networks, while the post-translational regulation remains largely unknown. Transmembrane ectodomain shedding is an important post-translational process orchestrating receptor expression and signal transduction through proteolytic cleavage of membrane proteins. Here, by targeting the sheddase A Disintegrin and Metalloprotease (ADAM)17, we defined a post-translational regulatory mechanism mediated by the ectodomain shedding in CD8 + T cells. Transcriptomic and proteomic analysis revealed the involvement of post-translational regulation in CD8 + T cells. T cell-specific deletion of ADAM17 led to a dramatic increase in effector CD8 + T cell differentiation and enhanced cytolytic effects to eliminate pathogens and tumors. Mechanistically, ADAM17 regulated CD8 + T cells through cleavage of membrane CD122. ADAM17 inhibition led to elevated CD122 expression and enhanced response to IL-2 and IL-15 stimulation in both mouse and human CD8 + T cells. Intriguingly, inhibition of ADAM17 in CD8 + T cells improved the efficacy of chimeric antigen receptor (CAR) T cells in solid tumors. Our findings reveal a critical post-translational regulation in CD8 + T cells, providing a potential therapeutic strategy of targeting ADAM17 for effective anti-tumor immunity.

biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The paper primarily explores the mechanism of action of an enzyme called A Disintegrin and Metalloprotease 17 (ADAM17) and the CD122 receptor axis to enhance the effector differentiation and anti-tumor immune capacity of CD8+ T cells. Specifically, the study addresses the following key issues: 1. **Regulation of CD8+ T cell effector function**: By targeting ADAM17, the research reveals a post-transcriptional regulatory mechanism that controls CD8+ T cell effector differentiation. 2. **Role of ADAM17**: Specific deletion of ADAM17 in T cells leads to a significant increase in CD8+ T cell effector differentiation and enhances the cells' ability to clear pathogens and tumors. 3. **Role of CD122**: Mechanistically, ADAM17 regulates the function of CD8+ T cells by cleaving CD122. Inhibiting ADAM17 can increase the expression level of CD122 and enhance the response to IL-2 and IL-15 stimulation. 4. **Application in CAR T cell therapy**: Interestingly, inhibiting ADAM17 in CD8+ T cells improves the efficacy of chimeric antigen receptor (CAR) T cells in the treatment of solid tumors. 5. **Validation in human CD8+ T cells**: Finally, the regulatory mechanism of ADAM17 on CD122 was also validated in human CD8+ T cells, providing potential applications for cancer immunotherapy. In summary, the main aim of this paper is to explore the role of ADAM17 in CD8+ T cell effector differentiation and anti-tumor immunity, and to propose a potential therapeutic strategy to enhance the anti-tumor activity of T cells.

Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8 + T cell effector differentiation and anti-tumor immunity

A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling

Immunomodulatory role of metalloproteinase ADAM17 in tumor development

ADAM10 modulates the efficacy of T‐cell‐mediated therapy in solid tumors

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

CD38-NAD(+) Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response

A Molecular Switch To Control Tnfr2 During Atherogenesis In Vivo

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

Abstract C039: Disruption of ADAM17-dependent cellular crosstalk inhibits tumor progression of pancreatic ductal adenocarcinoma

Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment

CD146 bound to LCK promotes T cell receptor signaling and antitumor immune responses in mice

A disintegrin and metalloproteinase domain 10 expression inhibition by the small molecules adenosine, cordycepin and N6, N6-dimethyladenosine and immune regulation in malignant cancers

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1

T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy

Targeting JMJD1C to selectively disrupt tumor T reg cell fitness enhances antitumor immunity

Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity

CTLA-4 Limits Anti-Cd20-mediated Tumor Regression